Prevention of Cardiovascular Events by Antiplatelet Agents After Acute Coronary Syndrome

Study on the Prevention of Cardiovascular Events by Antiplatelet Agents After Acute Coronary Syndrome

Prevention of cardiovascular events by antiplatelet agents after acute coronary syndrome

AReMIS (Antiplatelet and Recurrent Myocardial Infarction Study) To compare the relative risk of new myocardial infarction (recurrent myocardial infarction or 'rMI') in patients with a history of acute coronary syndrome ('ACS': unstable angina or myocardial infarction), using ticagrelor, clopidogrel or prasugrel (if applicable) or none of these treatments, where aspirin is considered a covariate.

Inclusion Criteria:

Patients aged 18 years or more, both genders, with an acute coronary syndrome (ACS), agreed to participate and able to respond to an interview in French and/or providing the details of an alternative replier (proxy) if necessary.

No Exclusion Criteria.